Skip to main content
. 2017 Dec 19;9(1):165–175. doi: 10.1007/s13300-017-0351-7

Fig. 1.

Fig. 1

Study design. E enrollment, BG biguanide, SU sulfonylurea, α-GI alpha-glucosidase inhibitor, TZD thiazolidine, DPP4i dipeptidyl-peptidase 4 inhibitor, SGLT2i sodium–glucose cotransporter 2 inhibitor, GLP-1RA glucagon-like peptide-1 receptor agonist